Avalo Therapeutics, Inc. - COMMON STOCK (AVTX)
CUSIP: 05338F306
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 22,853,024
- Total 13F shares
- 7,530,521
- Share change
- +800,252
- Total reported value
- $55,951,612
- Price per share
- $7.43
- Number of holders
- 33
- Value change
- +$4,829,815
- Number of buys
- 15
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05338F306:
Top shareholders of AVTX - Avalo Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13F
|
Company |
4.2%
|
970,359
|
$9,218,411 | — | 30 Sep 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
4.2%
|
967,000
|
$9,186,500 | — | 30 Sep 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.2%
|
967,000
|
$9,186,500 | — | 30 Sep 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
4.2%
|
967,000
|
$9,186,500 | — | 30 Sep 2024 | |
| BVF INC/IL |
13F
|
Company |
4.2%
|
967,000
|
$9,147,820 | — | 30 Sep 2024 | |
| Logos Global Management LP |
13F
|
Company |
2.4%
|
539,079
|
$5,121,251 | — | 30 Sep 2024 | |
| Commodore Capital LP |
13F
|
Company |
2.1%
|
483,000
|
$4,588,500 | — | 30 Sep 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.1%
|
483,000
|
$4,588,500 | — | 30 Sep 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.72%
|
164,092
|
$1,558,874 | — | 30 Sep 2024 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.31%
|
71,458
|
$678,851 | — | 30 Sep 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.2%
|
45,000
|
$425,700 | — | 30 Sep 2024 | |
| ARMISTICE CAPITAL, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
765,828
|
$397,771 | — | 26 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.05%
|
10,368
|
$98,081 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
10,111
|
$95,649 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
6,134
|
$58,273 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
5,601
|
$53,210 | — | 30 Sep 2024 | |
| James Archie Harrell Jr. |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
36,766
|
$19,096 | — | 10 Dec 2021 | |
| H. Jeffrey Wilkins |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
33,373
|
$17,334 | — | 10 Dec 2021 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
376
|
$3,572 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
329
|
$3,126 | — | 30 Sep 2024 | |
| Schond L. Greenway |
3/4/5
|
CFO |
—
class O/S missing
|
3,883
|
$2,017 | — | 10 Dec 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
10
|
$96 | — | 30 Sep 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
4
|
$38 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
2
|
$19 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
2
|
$19 | — | 30 Sep 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
2
|
$19 | — | 30 Sep 2024 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
1
|
$10 | — | 30 Sep 2024 | |
| Jaffetilchin Investment Partners, LLC |
13F
|
Company |
0%
|
1
|
$10 | — | 30 Sep 2024 | |
| Key FInancial Inc |
13F
|
Company |
0%
|
1
|
$10 | — | 30 Sep 2024 | |
| Parallel Advisors, LLC |
13F
|
Company |
0%
|
1
|
$10 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1
|
$10 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0%
|
1
|
$9 | — | 30 Sep 2024 | |
| Stephen Smolinski |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
400,000
|
— | — | 04 Jan 2022 | |
| Michael F. Cola |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
78,116
|
— | — | 01 Oct 2021 | |
| Sol J. Barer |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 15 Jun 2021 | |
| Joseph M. Miller |
3/4/5
|
Director |
—
class O/S missing
|
20,239
|
— | — | 31 Mar 2022 | |
| Suzanne Louise Bruhn |
3/4/5
|
Director |
—
class O/S missing
|
5,204
|
— | — | 10 Nov 2021 | |
| Phil Gutry |
3/4/5
|
Director |
—
class O/S missing
|
4,718
|
— | — | 01 Dec 2021 | |
| Magnus Persson |
3/4/5
|
Director |
—
class O/S missing
|
3,334
|
— | — | 20 Dec 2023 |
Institutional Holders of Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) as of Q4 2024
As of 31 Dec 2024,
Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,530,521 shares.
The largest 10 holders included
BVF INC/IL, Ikarian Capital, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Deep Track Capital, LP, Affinity Asset Advisors, LLC, TCG Crossover Management, LLC, COMMODORE CAPITAL LP, VANGUARD GROUP INC, and BOOTHBAY FUND MANAGEMENT, LLC.
This page lists
33
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
28
Q4 2024 holders
33
Holder diff
5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.